A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
- Conditions
- Myelofibrosis
- Registration Number
- NCT05444972
- Lead Sponsor
- AbbVie
- Brief Summary
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis.
Data from approximately 1000 participants will be collected. No participants will be enrolled in this study.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks.
There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 998
- Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)].
- Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
- Having received MF treatment in a clinical trial setting.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time from Diagnosis of Myelofibrosis (MF) to Initial Treatment Up to Week 156 Time from diagnosis of MF to initial treatment.
Duration of Second Treatment Up to Week 156 Duration of second treatment.
Duration of Initial Treatment Up to Week 156 Duration of initial treatment.
Duration of Subsequent Treatments Up to Week 156 Duration of subsequent treatments.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (66)
UAB Comprehensive Cancer Center /ID# 252767
🇺🇸Birmingham, Alabama, United States
Wellness Oncology & Hematology /ID# 255591
🇺🇸West Hills, California, United States
Brigham & Women's Hospital /ID# 254312
🇺🇸Boston, Massachusetts, United States
Gabrail Cancer Center Research /ID# 252768
🇺🇸Canton, Ohio, United States
Instituto FIDES /ID# 245526
🇦🇷La Plata, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires /ID# 244373
🇦🇷Ciudad Autonoma Buenos Aires, Ciuadad Autonoma De Buenos Aires, Argentina
Fundaleu /Id# 244371
🇦🇷Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, Argentina
Townsville University Hospital /ID# 246585
🇦🇺Douglas, Queensland, Australia
Royal Adelaide Hospital /ID# 246583
🇦🇺Adelaide, South Australia, Australia
Fiona Stanley Hospital /ID# 246584
🇦🇺Murdoch, Western Australia, Australia
Scroll for more (56 remaining)UAB Comprehensive Cancer Center /ID# 252767🇺🇸Birmingham, Alabama, United States